This video is adapted from 10.3390/gels12010025
This video examines a study in which dextran-based hydrogels were synthesized in dimethyl sulfoxide via free-radical polymerization using three structurally different crosslinking agents: divinyl benzene (DVB), diethylene glycol diacrylate (DEGDA), and 4,4′-di(methacryloylamino)azobenzene (DMAAazoB). Their morphology, swelling ability, mechanical properties, and potential for controlled release of the model substance (uracil) were investigated, with the results showing that the chemical structure and chain length of the crosslinking agents significantly influence the structural and functional properties of hydrogels. This video reports that hydrogels crosslinked with DMAAazoB exhibited the highest swelling ability at pH 3 and pH 6 (2552% and 1696%, respectively), attributed to protonation effects and sponge-like morphology, while simultaneously displaying the lowest mechanical strength (20 and 47 MPa). In vitro simulations of gastrointestinal digestion revealed that uracil was not released during the gastric phase, whereas release in the intestinal environment was substantial, particularly for Dex-DMAAzoB hydrogels (88.52%). This video notes that the absence of azoreductases in the simulated system suggests that drug release under real physiological conditions would likely be even more pronounced. The Dex-DMAAzoB hydrogel demonstrated a slight antibacterial effect, producing inhibition zones of 8 mm and 7 mm against Escherichia coli ATCC 8739 and Staphylococcus epidermidis ATCC 12228, respectively. In contrast, this video shows that the other hydrogel formulations exhibited no detectable antibacterial activity toward either bacterial strain, indicating their microbiological inertness and supporting their suitability as carrier matrices for antitumor drug delivery in colorectal cancer therapy. This video concludes that the obtained results confirm azo-crosslinked dextran hydrogels, with an optimized amount of crosslinking agent, are promising carriers for the targeted and controlled delivery of antitumor drugs to the colorectal region.